Related Experiment Video

Updated: May 23, 2026

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
04:41

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

No consistent evidence for association between mtDNA variants and Alzheimer disease

G Hudson1, R Sims, D Harold

  • 1Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, UK.

Neurology
|March 24, 2012
PubMed
Abstract

Insights

Mitochondrial DNA (mtDNA) variations are not compellingly linked to Alzheimer disease (AD). This large study and meta-analysis found no significant evidence supporting an association between common mtDNA variants and AD development.

Area of Science:

  • Genetics
  • Neuroscience
  • Mitochondrial Biology

Background:

  • Previous studies suggest a link between mitochondrial DNA (mtDNA) variations and Alzheimer disease (AD). However, inconsistent findings across studies create uncertainty regarding mtDNA's role in AD etiology.
  • The etiological contribution of mtDNA to AD pathogenesis remains unclear due to conflicting reports on specific variant associations.

Purpose of the Study:

  • To investigate the association between common mitochondrial DNA (mtDNA) variants and Alzheimer disease (AD).
  • To clarify the role of mtDNA in the etiology of AD by examining a large cohort and performing a meta-analysis.

Main Methods:

  • Genomic DNA was analyzed for 138 mitochondrial DNA (mtDNA) variants in a large cohort comprising 4,133 Alzheimer disease (AD) cases and 1,602 controls from three Caucasian populations.
  • Rigorous quality control was applied, with 3,250 cases and 1,221 controls included in the final analysis. A meta-analysis of existing data was also performed.

Main Results:

  • This study, the largest to date examining mtDNA variants and AD, failed to replicate previously reported associations.
  • Meta-analysis of all available data provided no statistical evidence for an association between common mtDNA variations and Alzheimer disease (AD).

Conclusions:

  • The current evidence does not strongly support a link between common mitochondrial DNA (mtDNA) variations and Alzheimer disease (AD).
  • The role of mtDNA in the development of AD remains uncertain and requires further investigation, potentially focusing on rare variants or different biological mechanisms.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...